NCT03663985 (FALCOn) is a clinical trial of Groupe FALCOn in Head and Neck Cancer, sponsored by Institut Claudius Regaud.

Who is sponsoring NCT03663985?

NCT03663985 is sponsored by Institut Claudius Regaud.

What drugs are being tested in NCT03663985?

Interventions in NCT03663985: Groupe FALCOn.

What condition does NCT03663985 study?

NCT03663985 studies Head and Neck Cancer, Head and Neck Carcinoma.

Is NCT03663985 still recruiting?

NCT03663985 is currently completed. Last updated 3 March 2020.

Last reviewed 2020-03-03 · How we verify

NCT03663985: FALCOn

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FALCOn (Facteur AnthropoLogique Cancer Orl)

Completed Last updated 3 March 2020

What this trial tests

trial testing Groupe FALCOn in Head and Neck Cancer in 206 participants. Completed in 31 May 2019.

Timeline

15 September 2018

Primary endpoint
31 December 2018

31 May 2019

Quick facts

Lead sponsor	Institut Claudius Regaud
Status	Completed
Study type	OBSERVATIONAL
Enrollment	206
Start date	15 September 2018
Primary completion	31 December 2018
Estimated completion	31 May 2019
Sites	1 location across France

Drugs / interventions tested

Groupe FALCOn

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Head and Neck Carcinoma — all drugs for Head and Neck Carcinoma →

Sponsor

Institut Claudius Regaud — full company profile →

Who can join

Eligibility, any sex, with Head and Neck Cancer or Head and Neck Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are no studies on practitioner-related factors influencing decision-making in the field of carcinology of aerodigestive carcinomas. The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ear, nose, and throat carcinology. Special attention will be paid to the practitioner's gender, age, geographical origin, place and institution of training, place of practice, volume of patients treated, access to or without reconstruction by microsurgery, his tendency or aversion to risk taking. * Main objectives : To determine the individual professional and non-professional characteristics influencing physicians' decision-making in oncology of aerodigestive carcinomas between choices: 1. Surgery 2. Radio and / or chemotherapy 3. Support care 4. Neo-adjuvant chemotherapy and reassessment * Secondary objectives : Identify if certain patient profiles may lead to heterogeneous treatment decisions i.e. Human Papillomavirus status, age, comorbidities, autonomy, etc.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The impact of physician's characteristics on decision-making inhead and neck oncology: Results of a national survey.
Chabrillac E, Lamy S, Grosclaude P, Cros F, et al · · 2022 · cited 3× · PMID 35500434 · DOI 10.1016/j.oraloncology.2022.105895

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Institut Claudius Regaud trials

Trials by the same sponsor.

NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03663985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
Last refreshed: 3 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03663985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing